- BioCina Pty Ltd. acquires exclusive rights to CelluTx’s RBPS technology for mcDNA production.
- The technology promises safer, more efficient gene therapy applications with potential tax incentives in Australia.
BioCina Pty Ltd., a global biologics Contract Development and Manufacturing Organization (CDMO), has announced the acquisition of exclusive rights to utilize CelluTx’s Recombination Based Plasmid System (RBPS) technology. This partnership is set to enhance minicircle DNA (mcDNA) production, a crucial component in cell and gene therapies.
The RBPS technology offers a novel approach to mcDNA production by enabling site-specific recombination within a bacterial host. This process effectively separates the gene of interest from the rest of the plasmid, resulting in a product that is less immunogenic and safer for in vivo use. The technology also boasts higher yields and the ability to produce larger minicircles, accommodating complex gene cassettes.
Mark W. Womack, CEO of BioCina, expressed his enthusiasm for the partnership, “We are pleased to announce our partnership with CelluTx enabling BioCina to exclusively provide this innovative technology to our clients around the world.”
The collaboration between BioCina and CelluTx is not only a testament to BioCina’s capabilities but also highlights Australia’s competitive edge in the biologics industry, offering up to 48.5% cash refund on tax incentives, making it an attractive destination for biologics companies.
The RBPS technology is already showing promise, with its application in GenomeFrontier’s CAR-T product scale-up, demonstrating the potential for advancing mcDNA production and expanding its applications in advanced therapeutics. This strategic move by BioCina is expected to bolster its position in the contract manufacturing market and provide a boost to the gene therapy sector.
Overview of outsourcing trends 
